Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

CSL Gains After UBS Says U.S. Sales May Beat Estimate

Updated on

CSL Ltd., the world’s second-largest maker of blood-based treatments, climbed the most in more than seven weeks in Australian trading after UBS AG said second-half sales in the U.S. may beat estimates.

CSL rose 2.8 percent, the most since April 14, to close at A$32.82, while Australia’s S&P/ASX 200 Index fell 0.8 percent.

U.S. sales of Melbourne-based CSL’s Privigen and Hizentra, treatments for immune-system disorders, may expand as much as 20 percent in the six months ending June 30 from a year earlier, Andrew Goodsall and Dan Hurren, analysts at UBS in Sydney, wrote in a note after the close of trading yesterday. That’s higher than the brokerage’s previous estimate of 12 percent.

Full-year profit will “meet or beat” UBS’s current estimates, said Goodsall and Hurren, who rate the stock “buy.” UBS is among 6 of 14 brokerages tracked by Bloomberg that recommend investors buy CSL shares. None has a sell rating.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.